Compare ABR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | SNDX |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | 653 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | ABR | SNDX |
|---|---|---|
| Price | $5.12 | $22.62 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $9.90 | ★ $38.69 |
| AVG Volume (30 Days) | ★ 3.9M | 2.3M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | N/A | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | $9.29 | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $4.86 | $9.42 |
| 52 Week High | $12.58 | $25.59 |
| Indicator | ABR | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.89 | 53.99 |
| Support Level | $4.99 | $22.40 |
| Resistance Level | $5.49 | $25.38 |
| Average True Range (ATR) | 0.19 | 1.30 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 37.90 | 38.55 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.